Although VEGF overexpression has been reported to correlate with cancer progression, anti-angiogenic therapies targeting the VEGF pathways have shown little or no effect in overall survival and progression-free survival in patients with metastatic BC (11). This evidence concerns the gene VEGFA and cancer.